Timothy M. D'Alfonso

Timothy D'Alfonso

Dr. D'Alfonso is a board-certified Anatomic Pathologist with subspecialty training and interest in Breast Pathology.

Prior to joining the faculty of the Department of Pathology and Laboratory Medicine, Dr. D'Alfonso completed residency training in Anatomic Pathology at New York-Presbyterian Hospital/Weill Cornell Medical Center, where he served as Chief Resident. He subsequently pursued subspecialty fellowship training in breast pathology at Weill Cornell. His research interests are focused on the pathogenesis, diagnosis, and treatment of breast malignancies. Along with clinical responsibilities and research pursuits, Dr. D'Alfonso is actively involved in resident and medical student education.


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicare
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • United Health Care
  • VNSNY CHOICE Medicare [Medicare]


D’Alfonso TM, Liu YF, Monni S, Rosen PP, Shin SJ. Accurately assessing HER-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed. Am J Surg Pathol 2010;34(4):575-581.

D’Alfonso TM, Shin SJ. Intramuscular lipoma arising within the pectoralis major muscle presenting as a radiographically detected breast mass. Arch Pathol Lab Med 2011;135(8):1061-1063.

 Carey SP, D’Alfonso TM, Shin SJ, Reinhart-King CA. Mechanobiology of tumor invasion: engineering meets oncology. Crit Rev Oncol Hematol 2012;83(2):170-183.           

D’Alfonso TM, Liu YF, Chen Z, Chen YB, Cimino-Mathews A, Shin SJ. SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients. J Clin Pathol 2013;66(5):409-414.

D’Alfonso TM, van Laar RK, Vahdat LT, Hussain W, Flinchum R, Brown N, Saint John L, Shin SJ. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high or low-risk for disease recurrence. Breast Cancer Res Treat 2013;139(3):705-715.

D’Alfonso TM, Wang K, Chiu YL, Shin SJ. Pathologic upgrade rates on subsequent excision when lobular carcinoma in situ is the primary diagnosis in the needle core biopsy with special attention to the radiographic target. Arch Pathol Lab Med 2013;137(7):927-935.

D’Alfonso TM, Scognamiglio T. Myofibroblastoma with chondroid metaplasia. Breast J 2013;19(5):549-551.

D’Alfonso TM, Ginter PS, Salvatore SP, Antonio LB, Hoda SA. Phylloides tumors with numerous thanatosomes (“death bodies”): a report of two cases and a study of thanatosomes in breast tumors. Int J Surg Pathol 2013;22(4):337-342.

D’Alfonso TM, Ginter PS, Liu YF, Shin SJ. Cystic hypersecretory (in situ) carcinoma of the breast: a clinicopathologic and immunohistochemical characterization of 10 cases with clinical follow-up. Am J Surg Pathol 2014;38(1):45-53.

Ginter PS, Mosquera JM, MacDonald TY, D’Alfonso TM, Rubin MA, Shin SJ. Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites. Hum Pathol 2014;45(4):709-716.

Nguyen MT, Stessin A, Nagar H, D’Alfonso TM, Chen Z, Cigler T, Hayes MK, Shin SJ. Impact of Oncotype DX Recurrence Score in the management of breast cancer cases. Clin Breast Cancer 2014;14(3):182-190.

Rohan TE, Xue X, Lin HM, D’Alfonso TM, Ginter PS, Robinson BD, Ginsberg M, Gertler FB, Glass AG, Sparano JA, Condeelis JS, Jones JG. Tumor Microenvironment of Metastasis and risk of distant metastasis of breast cancer. J Natl Cancer Inst 2014;106(7).

D’Alfonso TM, Hannah J, Chen Z, Liu YF, Zhou P, Shin SJ. Axl receptor tyrosine kinase expression in breast cancer. J Clin Pathol 2014 (in press).